No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - MaxCyte confirmed on Wednesday that trading of its shares on London's AIM market would cease at the close of trading, with the cancellation of its AIM listing taking effect at 0700 BST on Thursday.
It said the decision followed shareholder approval at the company's annual general meeting on 18 June.
The cell engineering company, which provides platform technologies for the development of next-generation cell therapeutics, said it would retain its listing on the Nasdaq Global Select Market in the United States, where its shares would continue to trade under the ticker MXCT.
MaxCyte noted that following the delisting, there would no longer be a public market in the UK for its common stock.
At 1149 BST, shares in MaxCyte were down 5.94% in London, at 150.5p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
